Researchers from Bright Peak Therapeutics AG presented the discovery and preclinical characterization of a novel first-in-class PD-1/interleukin-18 (IL-18) immunocytokine, BPT-567.
Expression of the tyrosine-protein phosphatase non-receptor type 22 (PTPN22) is restricted to hematopoietic cells where it serves critical functions in regulating T-cell signaling that have made PTPN22 the focus of potential future cancer immunotherapy.
Researchers from Astrazeneca plc described the development and preclinical evaluation of AZD-5335, a novel antibody-drug conjugate (ADC) consisting of folate receptor α (FR-α)-targeting antibody conjugated to a proprietary topoisomerase 1 inhibitor (TOP1i), being developed as a potential new therapeutic against ovarian cancer.
Heterogeneity, in both tumors and their microenvironment, limits the success of current cancer treatments. But it also provides opportunities. Heterogeneities “are not barriers to therapy, they are vulnerabilities to be exploited,” was how David DeNardo described his take at the 2023 annual meeting of the American Association for Cancer Research (AACR) on Sunday.
Pyramid Biosciences Inc. and Genequantum Healthcare (Suzhou) Co. Ltd. have entered into an exclusive license agreement to develop and commercialize GQ-1010, a potential best-in-class antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan).
Defence Therapeutics Inc. says it has successfully established a strategy conjugating mRNA molecules to Accum, the company’s core technology that enables precision delivery of vaccine antigens or antibody-drug conjugates in their intact form to target cells.
Protein-tyrosine phosphatase SHP-1 is a negative regulator of immune cell function and is broadly expressed in the hematopoietic compartment. Due to its role in immune cell signaling, SHP-1 may be explored as a target for tumor immunotherapy.
Contrary to current opinion, genomic instability is not the origin of cancer in patients with short telomere syndromes (STSs), researchers from the Johns Hopkins University School of Medicine reported April 2, 2023, in Cancer Cell. Instead, short telomeres appeared to cause memory T-cell dysfunction that increased the risk of a small number of tumor types in individuals with STS. Such syndromes can cause premature aging of different physiological systems.
CSPC Pharmaceutical Group Ltd. has received FDA clearance of its IND for a phase I trial of its antibody-drug conjugate CPO-301 for the treatment of advanced lung cancer with alterations in the EGFR gene or EGFR over-expression.
RSS
